2017 Q4 Form 10-Q Financial Statement

#000114420418005155 Filed on February 01, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2016 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.000M $1.030M
YoY Change -2.91% 18.39%
% of Gross Profit
Research & Development $580.9K $349.3K
YoY Change 66.3% -15.63%
% of Gross Profit
Depreciation & Amortization $724.00 $119.00
YoY Change 508.4%
% of Gross Profit
Operating Expenses $1.582M $1.376M
YoY Change 15.0% 7.54%
Operating Profit -$1.582M -$1.376M
YoY Change 15.0% 7.54%
Interest Expense $0.00 $25.57K
YoY Change -100.0% -82.21%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $390.0K -$1.400M
YoY Change -127.86% 20.69%
Income Tax
% Of Pretax Income
Net Earnings $389.2K -$1.402M
YoY Change -127.77% 21.17%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.01
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 150.1M shares 135.3M shares
Diluted Shares Outstanding 163.5M shares 135.3M shares

Balance Sheet

Concept 2017 Q4 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.960M $3.790M
YoY Change 30.87% 34.4%
Cash & Equivalents $4.958M $3.788M
Short-Term Investments
Other Short-Term Assets $70.00K $110.0K
YoY Change -36.36% 120.0%
Inventory
Prepaid Expenses $71.40K
Receivables
Other Receivables
Total Short-Term Assets $5.029M $3.898M
YoY Change 29.03% 35.89%
LONG-TERM ASSETS
Property, Plant & Equipment $9.927K $4.174K
YoY Change 137.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K
YoY Change
Total Long-Term Assets $13.43K $4.174K
YoY Change 221.68%
TOTAL ASSETS
Total Short-Term Assets $5.029M $3.898M
Total Long-Term Assets $13.43K $4.174K
Total Assets $5.043M $3.902M
YoY Change 29.24% 36.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $289.3K $270.0K
YoY Change 7.14% 0.8%
Accrued Expenses $180.0K $380.0K
YoY Change -52.63% 153.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $750.0K
YoY Change 177.78%
Total Short-Term Liabilities $470.5K $1.410M
YoY Change -66.62% 88.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.460M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $1.458M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $470.5K $1.410M
Total Long-Term Liabilities $1.458M $0.00
Total Liabilities $1.929M $1.410M
YoY Change 36.81% -28.01%
SHAREHOLDERS EQUITY
Retained Earnings -$29.11M
YoY Change
Common Stock $32.23M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.114M $2.490M
YoY Change
Total Liabilities & Shareholders Equity $5.043M $3.900M
YoY Change 29.31% 35.96%

Cashflow Statement

Concept 2017 Q4 2016 Q4
OPERATING ACTIVITIES
Net Income $389.2K -$1.402M
YoY Change -127.77% 21.17%
Depreciation, Depletion And Amortization $724.00 $119.00
YoY Change 508.4%
Cash From Operating Activities -$1.096M -$1.375M
YoY Change -20.3% 20.61%
INVESTING ACTIVITIES
Capital Expenditures $3.463K $4.293K
YoY Change -19.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.463K -$4.293K
YoY Change -19.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $63.39K $130.6K
YoY Change -51.45%
NET CHANGE
Cash From Operating Activities -$1.096M -$1.375M
Cash From Investing Activities -$3.463K -$4.293K
Cash From Financing Activities $63.39K $130.6K
Net Change In Cash -$1.036M -$1.249M
YoY Change -17.04% 9.54%
FREE CASH FLOW
Cash From Operating Activities -$1.096M -$1.375M
Capital Expenditures $3.463K $4.293K
Free Cash Flow -$1.099M -$1.379M
YoY Change -20.3% 20.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
1375931 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
1582373 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
1971549 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
71404 USD
CY2017Q3 us-gaap Cash
Cash
5994052 USD
CY2017Q4 us-gaap Cash
Cash
4958073 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9927 USD
CY2016Q4 us-gaap Revenues
Revenues
0 USD
CY2017Q4 us-gaap Revenues
Revenues
0 USD
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1026644 USD
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1001511 USD
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
349287 USD
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
580862 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1375931 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1582373 USD
CY2016Q4 us-gaap Interest Expense
InterestExpense
25570 USD
CY2017Q4 us-gaap Interest Expense
InterestExpense
0 USD
CY2016Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25570 USD
CY2017Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1971549 USD
CY2017Q4 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q4 dei Trading Symbol
TradingSymbol
ARTH
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
154052013 shares
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1458484 USD
CY2017Q4 us-gaap Liabilities
Liabilities
1929001 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
470517 USD
CY2017Q3 us-gaap Assets
Assets
6090083 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
150302 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32077871 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29114270 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3113903 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5042904 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
433531 USD
CY2017Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
168655 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
264876 USD
CY2017Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3430033 USD
CY2017Q3 us-gaap Liabilities
Liabilities
3863564 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
149943 USD
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31580022 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29503446 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
2226519 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6090083 USD
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
181241 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
289276 USD
CY2017Q4 us-gaap Assets
Assets
5042904 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
6079395 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
5029477 USD
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
85343 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7188 USD
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
13427 USD
CY2017Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
10688 USD
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1458484 USD
CY2017Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3430033 USD
CY2016Q4 us-gaap Share Based Compensation
ShareBasedCompensation
265662 USD
CY2017Q4 us-gaap Share Based Compensation
ShareBasedCompensation
434820 USD
CY2016Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
5529 USD
CY2017Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
0 USD
CY2016Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2286 USD
CY2017Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-13939 USD
CY2016Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-102644 USD
CY2017Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24400 USD
CY2016Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-178451 USD
CY2017Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12586 USD
CY2016Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1375002 USD
CY2017Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1095904 USD
CY2016Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
130556 USD
CY2017Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63388 USD
CY2016Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-69430 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
0 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
389176 USD
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150144575 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135319847 shares
CY2016Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1248739 USD
CY2017Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1035979 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5036476 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5994052 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3787737 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4958073 USD
CY2016Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
359150 USD
CY2017Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63388 USD
CY2016Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2017Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1971549 USD
CY2017Q4 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016Q4 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-108000 USD
CY2017Q4 us-gaap Depreciation
Depreciation
724 USD
CY2016Q4 us-gaap Depreciation
Depreciation
119 USD
CY2017Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2017Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3463 USD
CY2016Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4293 USD
CY2017Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3463 USD
CY2016Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4293 USD
CY2017Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2016Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
228594 USD
CY2017Q4 us-gaap Stock Issued1
StockIssued1
117 USD
CY2016Q4 us-gaap Stock Issued1
StockIssued1
0 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
6147 USD
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
5423 USD
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7226 pure
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944 pure
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0114 pure
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0240 pure
CY2017Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
225000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2017Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.37
CY2017Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
CY2017Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
CY2017Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
CY2017Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2017Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6178263 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1299763 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14634210 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14409210 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.39
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.39
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4428980 shares
CY2016Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
5500 USD
CY2017Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
3263753 USD
CY2015Q1 arth Gain Loss On Warrant Derivative Modification
GainLossOnWarrantDerivativeModification
624016 USD
CY2017Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
2996110 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154052013 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138182075 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154052013 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138182075 shares
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
163527032 shares
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135319847 shares
CY2017Q4 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><u>Derivative Liabilities</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company&#8217;s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for expected volatility, expected life, yield, and risk-free interest rate.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12611 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16074 USD
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y8M19D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y6M4D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12120302 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.36
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1237915 USD
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 USD
CY2017Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14409210 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1299763 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.39
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M18D

Files In Submission

Name View Source Status
0001144204-18-005155-index-headers.html Edgar Link pending
0001144204-18-005155-index.html Edgar Link pending
0001144204-18-005155.txt Edgar Link pending
0001144204-18-005155-xbrl.zip Edgar Link pending
arth-20171231.xml Edgar Link completed
arth-20171231.xsd Edgar Link pending
arth-20171231_cal.xml Edgar Link unprocessable
arth-20171231_def.xml Edgar Link unprocessable
arth-20171231_lab.xml Edgar Link unprocessable
arth-20171231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv484024_10q.htm Edgar Link pending
tv484024_ex31-1.htm Edgar Link pending
tv484024_ex31-2.htm Edgar Link pending
tv484024_ex32-1.htm Edgar Link pending